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ABSTRACT 
The current standard treatment of prostate cancer by androgen deprivation therapy 
involves using drugs such as bicalutamide (Casodex) to antagonistically block androgen 
receptors that are normally present within prostate cells. Usually, the therapy is successful in the 
short run at limiting the growth of prostate cancer. However, in virtually all cases tumors begin 
to grow aggressively again after several months of treatment and new therapies must be started. 
The mechanism by which these prostate cells transform from androgen sensitive to androgen 
independent and anti-androgen resistant is unclear. In this study, we investigated the role of 
microRNAs, small 15 to 18 nucleotide regulatory RNAs, in regulating the desensitization of 
prostate cancer cells to the androgen receptor antagonist drug bicalutamide.  
In order to identify significant microRNAs, quantitative PCR was used to obtain genome-
wide microRNA expression levels of 885 human microRNAs at different timepoints for 
androgen sensitive LNCaP cancer cells treated with bicalutamide and for untreated control cells 
in tissue culture.  Analysis of microRNA expression by clustering analysis and by statistical 
comparisons of treatment groups resulted in identification of 28 microRNAs that have altered 
expression in the progression process. In silico target prediction analysis was performed with the 
microRNAs shown to have altered expression, and a group of genes predicted to be under 
microRNA regulatory control during cancer progression to resistance was identified. A 
microRNA expression profile can be useful in developing more effective prognostic and 
therapeutic tools for prostate cancer.  
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INTRODUCTION 
Prostate cancer in men represents one of the most persistent challenges to modern 
medicine both in terms of its widespread rate of occurrence and in its evasiveness to treatment. 
The statistics for prostate cancer are astonishing; according to American Cancer Society 
estimates, 1 in 6 men will be diagnosed with prostate cancer in their lifetime and 1 in 36 will die 
from it.  The Center for Disease Control and Prevention reports prostate cancer as the most 
diagnosed cancer in men for all races including populations of Hispanic origin with a combined 
incidence rate of 156.9 in 100,000. All fields of cancer research, and especially those dealing 
with prostate cancer, require our continued dedication in advancing our understanding of the 
mechanisms of carcinogenesis and progression as well as the optimal clinical treatments.  
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BACKGROUND 
Clinical Treatment of Prostate Tumors 
The majority of patients who present with well localized prostate carcinoma undergo 
radical prostatectomy, radiation therapy, or active surveillance. When prostate cancer is not well 
localized, standard therapy for patients with more metastatic but androgen-sensitive disease 
states is the administration of a combination of drugs used to simultaneously block androgen 
receptor function in prostate tissue as well as deplete the levels of androgen produced by the 
testes. The therapeutic basis of this tactic is that prostate cancer tissue requires stimulation by 
androgen in order to continue to survive and proliferate. Androgen depletion can be achieved by 
orchiectomy or by using a gonadotropin-releasing hormone (GnRH) analogue that decreases the 
production of luteinizing hormone in the pituitary by strongly binding the GnRH receptor and 
causing its down-regulation. At the same time, non-steroidal anti-androgen drugs such as 
flutamide (Eulexin), nilutamide (Nilandron, Anandron), or bicalutamide (Casodex) are used to 
antagonistically block prostate androgen receptors (Sharifi et al., 2010). From this point on the 
disease course is fairly predictable. First, there is a noted decline in serum prostate specific 
antigen (PSA) level and a regression of the tumor. After a period of time, usually 18 to 24 
months, PSA levels begin to rise, tumor progression returns, and prostate cancer symptoms 
become more pronounced (Chen et al., 2009). This stage of prostate cancer is characterized by 
resistance to the anti-androgen and androgen deprivation therapy as well as more aggressive 
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metastatic phenotypes. Patients with metastatic androgen independent prostate cancer must seek 
stronger chemotherapies such as Docetaxel and Estramustine (Petrylak et al., 2004).  
It should be noted that the clinical use of anti-androgen drugs for the treatment of prostate 
cancer has potential widespread detrimental effects on the body. Some of the long-term effects of 
androgen deprivation therapy include fatigue, loss of bone density, decreased libido and sexual 
function, and increases in the rates of diabetes and cardiovascular disease (Alibhai et al., 2006). 
Decrease in a patient’s quality of life could also come as a result of a decrease in cognitive 
function, though this relationship is not well established (Alibhai et al., 2010; Tadros and 
Garzotto, 2011). Nevertheless, it is apparent that the long-term side effects of androgen 
deprivation therapy and the certain progression to drug resistance warrants improved clinical 
screening techniques for patient-specific drug effectiveness as well as investigation into new 
therapies. 
Androgen Receptor 
The primary ligands for normally functioning androgen receptor are the lipophilic steroid 
hormone testosterone and the testosterone derivative dihydrotestosterone (the product of 5α-
reductase). Androgen signaling is crucial for regulating the development and differentiation of 
the male reproductive organs, including the prostate, as well as the secondary sex tissues. 
Androgen and its receptor continue to mediate the normal maintenance and function of these 
tissues throughout life. Androgen receptor itself is present in the cytoplasm of prostate (and 
other) tissues in its inactive form as a 110 kDa class I steroid receptor protein bound to various 
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stabilizing proteins such as hsp90, hsp70, and hsp56 (Roy et al., 2001). Lipophilic steroid 
androgens are able to diffuse across the lipid bilayer of the cytoplasmic membrane, and upon 
binding to the ligand-binding domain of the androgen receptor, cause a conformational change 
that leads to dissociation of heat-shock proteins, phosphorylation by kinases, translocation to the 
nucleus, and dimerization (Mangelsdorf et al., 1995). 
In the nucleus, androgen receptor binds to specific sequences in the genomic DNA 
referred to as androgen response elements (AREs). Transcriptional co-activators are recruited to 
induce transcription of genes under androgen receptor control, like PSA (Riegman et al., 1991). 
PSA is commonly used in research labs and clinics as a reporter of androgen receptor activity, 
with high serum levels of PSA suggestive of prostate cancer. In prostate tumors the expression of 
androgen-regulated genes leads to cell survival and proliferation. For example, a recent study 
showed that the expression of TM4SF1 is under androgen control and that TM4SF1 
overexpression increases prostate cancer cell migration (Allioli et al., 2011). There are also some 
lines of evidence that suggest androgen receptor has additional roles in activating growth factor 
pathways by direct protein-protein interaction, such as through interaction of androgen receptor 
and the transcription factor AP-1 (Fronsdal et al., 1998). Androgen receptor pathways are 
involved in many cellular processes, but it is clear that the main result of androgen receptor 
signaling in prostate cancer is the survival of cancerous prostate cells.  
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Androgen Independence 
The earliest work on the effects of hormones on prostate cancer was performed by 
Huggins and Hodges when they did their Nobel Prize winning work on androgen dependence of 
prostate carcinoma in humans and suggested androgen ablation (depletion of circulating 
androgen levels) as a treatment for prostate cancer (Huggins, 1957). Several studies have shown 
that steroidal anti-androgen drugs, like cyproterone acetate, and non-steroidal anti-androgen 
drugs repress growth of prostate cancer cells in vitro (Bologna et al., 1995; Kokontis et al., 
1998). However, clinical use of these drugs leads to castration resistant relapse in virtually all 
cases. Several studies have successfully established androgen independent cell-lines by 
prolonged passage in hormone-depleted media. Androgen dependent LNCaP-104S cells begin to 
die in androgen-depleted media and show a biphasic response to androgen, with low androgen 
levels inducing growth and high androgen levels repressing growth but inducing greater PSA 
production (Kokontis et al., 1994; Lee et al., 1995). On the other hand, androgen independent 
LNCaP-104R cells exhibit unrepressed growth in androgen-depleted media. Interestingly, the 
growth of LNCaP-104R cells is repressed by treatment with androgen levels that normally 
induce proliferation of LNCaP-104S cells (Kokontis et al., 1998).  
The molecular mechanisms of progression from androgen sensitive to androgen 
independent during treatment with androgen receptor antagonist drugs like Casodex remains 
largely unknown. Several studies over the years have shown that androgen-independent prostate 
cells exhibit increased androgen receptor expression and activity (Culig et al., 1999; Kokontis et 
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al., 1998). This increase in androgen receptor activity suggests a functional role for androgen 
receptor in the maintenance of proliferation in androgen independent cancer. There are basically 
three theories proposed for the role of androgen receptor in the acquisition of androgen 
independence: activation of androgen receptor by secondary ligand, ligand independent 
activation of androgen receptor, or activation of an androgen receptor bypass mechanism.  
Some evidence points towards the possibility that the androgen receptor becomes 
activated by certain non-steroidal growth factors and cytokines like IGF-1, KGF, EGF, and IL-6 
in the androgen independent state (Jenster, 2000). One study showed that a point mutation in 
androgen receptor changes the effects of cyproterone acetate and the non-steroidal anti-androgen 
hydroxyflutamide so that the receptor is capable of recruiting the same co-regulators as if it were 
activated by androgen, essentially conferring agonist properties on the anti-androgen molecules 
(Berrevoets et al., 2002). Studies have also identified androgen receptor mutations that greatly 
increase the affinity of the androgen receptor steroid binding domain to very low androgen 
concentrations (Thin et al., 2003). The increased affinity to androgen may mean that the 
extremely low amount of androgen produced during implementation of an androgen deprivation 
strategy can preferentially bind the receptor. Additionally, strong amplification of the androgen 
receptor seen in some androgen independent prostate tumor samples, as well as the LNCaP-104R 
cell line, could increase the ability of the receptor to be activated by secondary ligand, possibly at 
a site separate from the androgen-binding domain (Ford et al., 2003).  
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On the other hand, it may be that a ligand is not required for activation. It has been shown 
that the androgen receptor is capable of ligand-independent interaction with the transcriptional 
coactivator SRC1 in the nucleus, causing transcription at certain promoters in the absence of 
androgen (Powell et al., 2004). It has also been proposed that an androgen receptor bypass 
mechanism might be important to progression, mediated through cytokines or other survival 
factors. One recent microarray investigation found that the proteins TWIST1, VAV3, and DKK3 
could be important to a bypass pathway, resulting in downstream expression of survival factors 
(Marques et al., 2010). 
MicroRNA 
 The apparent elusiveness of a direct mechanism for the regulation of prostate cell 
progression to CDX-resistance has led many to suggest that a more complex regulatory network 
is at play. In fact, the progression mechanisms of many cancer types appear to be mediated by 
complex regulatory processes consisting of protein and RNA elements. Recent evidence suggests 
that the progression of multiple human cancers, including prostate cancer, is mediated by a 
growing class of small non-coding RNAs called microRNAs (miRNA). These short, ~22 
nucleotide-long, single-stranded RNAs regulate human genes by binding to imperfectly 
complementary sequences on the 3’ un-translated region (3’ UTR) of target mRNA transcripts. 
Binding of the miRNA and its associated silencing complex to the mRNA transcript inhibits 
translational elongation, thus leading to post-transcriptional negative gene regulation (see Mode 
of Regulation). In some instances there is potential for great complexity in gene regulation by 
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miRNAs, as studies have shown that a single miRNA may target up to 200 different genes and 
that a single gene can be regulated by many miRNAs (Lim et al., 2005). The first miRNA 
identified, lin-4, was found to be implicated in the larval development of C. elegans (Lee et al., 
1993). Lin-4 was also the first miRNA to have its regulatory function characterized when it was 
discovered that lin-4 targets the mRNA transcript of the protein-coding gene lin-14 and 
temporally mediates transition between larval stages L1 and L2 (Wightman et al., 1993). Since 
then, several hundred human miRNAs have been identified and implicated in a diverse array of 
cellular processes including differentiation, cell proliferation, apoptosis, stress response, 
immunity, transcription, and tumorigenesis. 
Biogenesis 
Genes encoding miRNAs are found throughout the human genome with a large number 
of miRNA genes believed to be transcribed as polycistronic units utilizing their own promoters 
(Cai et al., 2004). However, some miRNAs have been found encoded in the intronic regions of 
other known genes (Lagos-Quintana et al., 2001). MiRNA genes are transcribed by RNA 
Polymerase II into long transcripts of several thousand bases that are then cleaved by the RNase 
III enzyme Drosha and its cofactor DGCR8 while in the nucleus. The resulting pri-miRNA is 
~70 nucleotides long and forms an imperfect hairpin-loop structure. Active transport of the pri-
miRNA out of the nucleus and into the cytoplasm is mediated by the nuclear membrane proteins 
Exportin-5 and RAN-GTP. Once in the cytoplasm the pre-miRNA transcript comes into contact 
with the enzyme Dicer and the RNA-binding protein TRBP which cleave the hairpin structure 
from the transcript, leaving an imperfectly complementary miRNA/miRNA* duplex consisting 
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of the guide strand mature miRNA sequence and the passenger strand miRNA. The guide strand 
of the miRNA/miRNA* duplex is preferentially incorporated into a multi-protein RNA-induced 
silencing complex (RISC) referred to as the miRISC, similar to the siRISC involved in RNAi 
silencing (Kim, 2005; Lee et al., 2002).  
Mode of Regulation 
Regulation of translation by miRNAs has been seen across eukaryotic and bacterial 
domains, and even in archaea. The bulk of miRNA research has focused on eukaryotic gene 
regulation, and it appears that differences exist in the modes of miRNAs translational repression 
between plants and animals. Generally, miRNA gene regulation in plants involves near perfect 
sequence complementarity between guide strand miRNA and mRNA target, inducing mRNA 
degradation through the RNAi pathway. Additionally the miRISC of plants binds the target 
mRNA transcript at sites within the coding region of the mRNA (Hannon, 2002). A conserved 
Argonaute protein in the RISC (Ago2 in humans) mediates the RNA-cleaving “slicer” activity of 
the complex where perfect miRNA/mRNA base pairing occurs. The only mammalian miRNA 
known to lead to mRNA cleavage is miR-196 when it binds to Hoxb8 mRNA (Yekta et al., 
2004). Human miRNAs generally do not exhibit perfect sequence complementarity and do not 
induce mRNA degradation. As part of the miRISC, the guide strand sequence targets binding of 
the miRNA to semi-complementary sites on the 3’ UTR of target mRNA sequences. The 
translation of these target genes is repressed due to the association of miRISC with the transcript 
(Esquela-Kerscher and Slack, 2006; Pillai et al., 2005). Two models have been proposed for 
miRNA-induced translational repression, and both involve processing bodies (PBs) in the 
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cytoplasm. PBs are known to mediate normal mRNA degradation and turnover. In the first 
model, the miRISC bound at the mRNA 3’ UTR interacts with the 5’ m7Gppp cap. This 
interaction interferes with recruitment of the E1F4E translation factor that is responsible for 
directing the transcript to the ribosome. Translationally repressed mRNAs are then directed to 
PBs for degradation or possibly storage. In the second model initiation is not affected, but 
binding of the miRISC to the 3’ UTR directs the mRNA to PBs where translation cannot occur 
(Pillai, 2005).  
Roles for MicroRNAs in Cancer 
The relatively recent emergence of high-throughput miRNA expression profiling 
techniques has begun to shed light on the various roles that miRNAs play in cancer. Microarray 
studies have shown that aberrant miRNA expression is correlated with several human cancers 
and that many miRNAs can be classified as oncogenes or tumor suppressor genes. The first 
miRNAs to have their expression associated with human cancer were miR-15a and miR-16-1. 
They have been shown to target the tumor-suppressor survival gene Bcl-2 and to be down-
regulated in B-cell chronic lymphocytic leukemia (Cimmino et al., 2005). Other examples of 
cancer-related miRNAs are miR-143 and miR-145, which are down-regulated in many cancer 
cell-lines (breast, prostate, cervical, and lymphoid cancer) as well as in colorectal tumors (Iorio 
et al., 2005; Michael et al., 2003). The conserved expression pattern across multiple cancer types 
indicates a generalized tumor suppression function of these miRNAs. The miRNA oncogene 
miR-21 has been found to be greatly overexpressed in glioblastoma tumors where it inhibits 
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apoptosis (Chan et al., 2005; Ciafre et al., 2005). Up-regulation of miR-21 expression has also 
been shown in breast cancer and prostate cancer where this miRNA may potentially have an 
oncogenic function (Iorio et al., 2005). The first class of miRNAs shown to regulate an oncogene 
was the let-7 miRNA family, which mediates expression of the Ras oncogene (Johnson et al., 
2005). It has been found that among lung cancer patients let-7 miRNA is most down-regulated in 
those that exhibit poor post-operative survival and overall poor prognosis. Additionally, 
expression of let-7 in lung cancer tissue has been shown to inhibit proliferation (Takamizawa et 
al., 2004). 
MicroRNA Regulation in Prostate Cancer 
With the overwhelming evidence that miRNAs have roles in various cancers, it is not 
surprising that there are recent indications that several miRNAs are implicated in the 
tumorigenesis and progression of prostate cancer (Catto et al., 2011). MiR-221 and miR-222 
have been shown to be up-regulated in androgen independent prostate cancer cell lines and to 
target the p27/kip1 tumor suppressor gene (Sun et al., 2009). High throughput microarray 
analysis of miRNA expression in prostate cancer cell lines shows that miR-21 expression is 
induced by androgen-stimulated androgen receptor and, indeed, that miR-21 alone is sufficient 
for maintaining a castration-resistant phenotype in prostate tumors in vivo (Ribas et al., 2009). 
Interestingly, it has also been shown that miR-21 targets PDCD4 and PTEN, two known anti-
survival genes (Lu et al., 2008; Papagiannakopoulos et al., 2008). MiRNAs of the miR-17-92 
family target the degradation of E2F transcription factor mRNA. In fact, it has also been shown 
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in prostate cancer cell lines that transcription factors of the E2F family are responsible for 
transcription of miR-17-92 family miRNAs. It is believed that a miRNA-mediated regulatory 
feedback loop is in place to control E2F expression here.  
Androgen-induced AR has also been shown to mediate expression of miR-125b. This 
miRNA inhibits translation of Bak1 and induces androgen independent growth in transiently 
infected prostate cancer cells (Shi et al., 2007). One study found that miR-146a is down-
regulated in androgen-independent prostate cancer cells and proposed a possible mechanism of 
androgen independence by showing the negative regulation of the ROCK1 oncogene by miR-
146a (Lin et al., 2008). The miRNA miR-145 is down-regulated in many cancers including 
prostate cancer and has been shown to target the BNIP3 gene. Low expression levels of miR-145 
and high BNIP3 expression levels in prostate tumors are associated with unfavorable patient 
outcomes (Chen et al., 2010). Given the numerous examples of miRNAs implicated in prostate 
cancer, it is hypothesized that miRNAs play essential roles in the progression of prostate cancers 
to Casodex resistance.  
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OBJECTIVE OF THE STUDY 
This study aimed to investigate the deregulation of miRNAs in human prostate cancer 
and the possible functional roles of deregulated miRNAs in the progression of prostate cancer 
cells toward anti-androgen resistance. Several major aspects of the study should be noted. Our 
primary focus was the measurement of miRNA levels at timepoints during anti-androgen 
treatment so that we could track time dependent miRNA changes that may have regulatory 
consequences. Due to the apparently complex nature of the androgen independence mechanism, 
a time dependent approach to screening miRNA expression during progression was central to the 
experimental design. Another important aspect of the study was the comparison of miRNA 
expression levels in anti-androgen treated cells to timepoint-paralleled androgen depleted cells so 
that we could isolate miRNAs that are deregulated due to the effects of anti-androgen binding to 
androgen receptor (and possibly additional mechanisms) separate from the effects of general 
androgen deprivation. Few studies have been so precise in their distinction between the changes 
that occur during castration resistance and anti-androgen resistance. The third focus of the study 
was to make use of the enormous amount of bioinformatics research that has been carried out to 
develop miRNA target prediction techniques. Several labs have created algorithms with the aim 
of predicting which mRNA transcripts specific miRNAs target. These algorithms that take 
several binding factors into account and the prediction results are made publically available 
online. A large portion of this study utilized in silico analysis techniques. 
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MATERIALS AND METHODS 
Experimental Plan 
The experimental plan was comprised of two phases: 
• M1 – Data acquisition, consisting of cell culture and treatment, western blot, and 
miRNome screening by qPCR 
• M2 – Data analysis, consisting of statistical analysis of expression data and in 
silico target prediction 
M1. Cell culture and cell treatment 
Principle 
The LNCaP cell line is an androgen sensitive prostate cancer cell line widely used in 
androgen deprivation experiments. Originally isolated from a lymph node metastasis of a 
primary prostate tumor, LNCaP cells express androgen receptor containing a T868 to A868 
mutation in the steroid binding domain. This mutation increases the affinity of the receptor 
protein for some anti-androgen molecules, including bicalutamide, and allows the signaling 
effects of anti-androgens to be more easily studied.  (Veldscholte et al., 1992; Veldscholte et al., 
1990). LNCaP-104S and LNCaP-104R1 are the sub-lines used in this study. LNCaP-104S cells 
are androgen sensitive and require androgen stimulation for growth. The line was established by 
selecting an LNCaP clone that demonstrated maximal proliferation with stimulation by 0.1 nM 
of synthetic androgen (Kokontis et al., 1994). The LNCaP-104R1 line was created by prolonged 
15 
 
passage in androgen depleted media for several months (80 to 100 passages) and is characterized 
as having a moderately aggressive drug resistant phenotype. LNCaP-104R1 cells grow 
unrepressed in androgen-depleted media but are repressed by levels of androgen that induce 
maximal LNCaP-104S proliferation (Kokontis et al., 1994). LNCaP-104R1 cells were utilized so 
that miRNA expression during anti-androgen treatment could be compared to expression in an 
established androgen independent line. 
Experimental design 
Cell culture of androgen sensitive LNCaP-104S cells was maintained before drug 
treatment in DMEM/10% FBS and 1 nM DHT with passage at 70% confluency. Culture of 
androgen independent LNCaP-104R1 cells was maintained in DMEM/10% FBS with passage at 
70% confluency. All treatments of LNCaP-104S cells were initiated by 48 hours of androgen 
depletion in DMEM/10% charcoal-stripped FBS (CS-FBS) media. For protein experiments, 
LNCaP-104S cells were treated with either 10 nM DHT or 5 µM Casodex (CDX) and harvested 
at zero hour, 24 hours, 48 hours, and 72 hours timepoints. For qPCR miRNA screening, LNCaP-
104S cells were treated with 5 µM Casodex in DMEM/10% CS-FBS media or only DMEM/10% 
CSFBS and harvested at one week and three weeks timepoints. LNCaP-104S and LNCaP-104R1 
cells were also harvested at zero hour timepoint (before treatment with CDX). 
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M1. SDS-PAGE and western blot 
Principle 
The standard technique for resolving and identifying proteins from extracted cellular 
lysates is SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) followed by 
transfer to a protein-binding membrane, such as a PVDF (polyvinylidene fluoride) membrane, 
and western blot procedure using a primary antibody specific for the protein of interest. SDS-
PAGE involves denaturing extracted proteins by boiling in the presence of sodium dodecyl 
sulfate and with the reducing agent β-mercaptoethanol. Besides general denaturation, β-
mercaptoethanol reduces any tertiary disulfide linkages. Sodium dodecyl sulfate binds to and 
linearizes denatured polypeptides and imparts a uniform negative charge on all peptides. In this 
way, all protein subunits can be resolved by electrophoresis based only on size. Electrophoretic 
separation is performed in a thin polyacrylamide gel. Small pores in the bis-acrylamide lattice 
allow smaller polypeptides to migrate at a faster rate toward the anode when an electric current is 
applied. A standard protein ladder is run simultaneously so that the sizes of proteins can later be 
ascertained. 
Transfer of the separated proteins is achieved by applying an electric current in a 
direction such that the negatively charged polypeptides migrate out of the gel and bind to an 
adjacent piece of protein-binding membrane. After staining the membrane with India ink to 
visualize the sample lanes, blocking with milk proteins ensures that all the protein-binding sites 
on the membrane are unavailable. Next, each lane is incubated with an appropriate concentration 
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of primary antibody specific for the protein of interest. After several rounds of rinsing to remove 
excess antibody and another round of blocking, the blot is incubated with an appropriate 
concentration of secondary antibody. The secondary antibody specifically binds to the constant 
regions of all immunoglobulins produced by a given species. The secondary antibody that is used 
is determined by the source of the primary antibody. The secondary antibody is also conjugated 
to a chemical that provides a means of visualization, commonly the enzyme horseradish 
peroxidase (HRP) which produces a fluorometric molecule in the presence of its substrate. When 
HRP-conjugated secondary is used, the protein of interest can easily be visualized by addition of 
the HRP substrate and developing on autoradiography film or with a western blot visualization 
system.  
Experimental design 
LNCaP-104S cells were maintained in CS-FBS for 48 hours and then treated with CDX 
or DHT. Cell samples were harvested by trypsinization at the following timepoints: zero hour, 24 
hours, 48 hours, and 72 hours. Cells were lysed using the freeze-thaw method with Halt 
phosphatase inhibitor. Protein concentration was measured by Bradford assay and proteins were 
resolved by SDS-PAGE separation. After transfer to PVDF membrane, western blot for 
androgen receptor was performed with mouse monoclonal IgG1 anti-AR primary antibody (U.S. 
Biological, Swampscott, MA) (1:2,500 in TBS-T/5% milk) and HRP-conjugated goat polyclonal 
IgG anti-mouse secondary antibody (Jackson ImmunoResearch Laboratories, Inc, West Grove, 
PA) (1:20,000 in TBS-T/5% milk). GAPDH was used for loading control. Western blots were 
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visualized by adding West Femto chemiluminescent substrate (ThermoFisher Scientific, 
Waltham, MA) to the secondary-probed membrane and then exposing and developing on 
autoradiography film. 
M1. Reverse transcription 
Principle 
Due to the requirement of template DNA when carrying out qPCR reactions for cell 
expression studies, it is usually necessary to convert the RNA isolated from a sample of cells to 
complementary DNA sequences (cDNA) for amplification. The reverse transcriptase enzyme 
was discovered in retroviruses that use it to insert viral genetic code into the DNA genomes of 
infected cells (Rodgers et al., 1995). In the lab, reverse transcriptase isolated from retroviral 
sources is added to RNA samples along with oligo-deoxythymidine primers, which bind to poly-
adenosine tails of mRNA transcripts. Small RNAs are not expressed with poly-adenosine tails so 
this step necessitates first adding poly-adenosine to all RNAs in the sample using a poly-
adenylate ligase. Once tails have been added and cDNA has been created from the RNA 
sequences in the sample, expression screening by qPCR can commence. 
Experimental design 
Cells were harvested by trypsinization and pellets were lysed with SBI Cells-to-Cts lysis 
buffer. SBI DNase I buffer was used to degrade DNA in the lysate. The SBI System Biosciences 
QuantiMir Small RNA Quantitation kit was used to tag all small RNAs in the lysate with poly-
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adenylate tails, bind universal oligo-deoxythymidine primers, and convert total RNA to cDNA 
with reverse transcriptase. 
M1. Quantitative polymerase chain reaction 
Principle 
The quantitative polymerase chain reaction technique is used to quantify the number of 
DNA copies of any specific sequence in a mixture of template DNA. It is a derivative of the 
more simple DNA amplification technique called the polymerase chain reaction. The standard 
polymerase chain reaction (PCR) is used to amplify the number of copies of a specific DNA 
sequence present in a reaction mixture. The required components of a PCR reaction mixture are 
as follows: forward and reverse primers for the DNA sequence of interest, DNA polymerase with 
a high temperature range (such as Taq polymerase), dNTPS, optimized cationic PCR buffer 
(usually containing potassium and magnesium ions), and the template DNA mixture. Using a 
thermocycler, the reaction mixture is subjected to successive rounds of temperature changes each 
consisting of a DNA denaturation phase of ~95°C, a primer annealing phase of ~60°C, and a 
transcript elongation phase of ~72°C. After approximately 30 cycles, the number of copies of a 
DNA sequence of interest will be have been amplified by several orders of magnitude. PCR 
amplification is extremely useful and has become central to almost all other DNA research 
techniques.  
Quantitative real time PCR (qPCR) takes advantage of the exponential nature of PCR 
amplification and the quantitative aspects of spectrophotometry to quantify the initial amount of 
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any specific DNA sequence in a sample of template DNA. One method of doing this is to add 
SYBR green reporter dye to the PCR reaction mixture and then perform the PCR reaction on a 
specialized quantitative thermocycler. SYBR green dye binds to double stranded DNA as it is 
synthesized in the PCR reaction. Upon binding to double-stranded DNA the emission properties 
of SYBR green dye changes so that it emits green light (λ of ~522 nm) when excited by a laser, 
allowing the amplification of DNA to be measured in real time. For most data analysis methods, 
the qPCR thermocycler measures the green light emission of each well in a reaction plate and 
then calculates the exact PCR cycle at which the total green light emission from a well reaches a 
predefined threshold value (i.e. the total amount of amplified dsDNA in a well reaches a 
predefined value). To be valid, the threshold fluorescence must fall within the exponential phase 
of DNA amplification. This cycle number is referred to as the cycle threshold value (Ct). When 
used in conjunction with reverse transcription, quantitative polymerase chain reaction is a 
powerful method of quantifying RNA expression levels of genes. Isolated RNA from a sample 
must first be converted to cDNA by reverse transcriptase, and then qPCR can be used to measure 
levels of cDNA. 
Experimental design 
Genome-wide human miRNAs were screened by reverse transcription to cDNA and then 
SYBR green qPCR reaction on an ABI 7900 HT real time thermocycler. MiRNA-specific 
primers were provided in the SBI System Biosciences miRNome profiling kit encompassing 885 
human miRNAs and three endogenously expressed small RNAs for plate controls (Human U6 
snRNA, RNU43 snoRNA, and Hm/Ms/Rt U1 snRNA). Additionally, universal oligo-
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deoxyadenosine reverse primers provided in the SBI System Biosciences kit were used in the 
qPCR reaction. A Ct value was obtained for each miRNA that amplified without error. All plate 
controls were amplified without error. 
M2. Delta-delta-Ct analysis 
Principle 
Several factors are considered during experimental design and multiple strategies have 
been developed for analyzing qPCR expression data. For experiments that require the calculation 
of an absolute quantity of template DNA, accurate analysis necessitates the creation of a standard 
curve using standard reactions of known template quantity and then comparison to the test Ct 
value. On the other hand, most expression experiments do not require absolute quantification, but 
rather make use of relative expression quantification compared to some control group. If this is 
the case, the most common method of data analysis is the delta-delta-Ct method (ΔΔCt method) 
(Cikos et al., 2007). 
 The ΔΔCt method requires no standard curve, is generally easier to perform than the 
standard curve method, and involves a simpler calculation than most other analysis methods 
(Livak and Schmittgen, 2001). In addition to having to include a control group in the 
experimental design, the ΔΔCt method calls for the inclusion of a set of reactions to amplify 
endogenously expressed control genes (housekeeping genes) called plate controls to normalize 
the expression data for plate-wide variations in amplification efficiency. For most mRNA 
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expression studies plate control genes such as GAPDH are used, while in miRNA expression 
studies endogenously expressed housekeeping small RNAs are used.  
To accurately analyze expression data using the ΔΔCt method, it is helpful to determine 
gene-specific average amplification efficiency for each gene being measured. This can be done 
several ways, but the gene-specific efficiency is usually calculated by running qPCR reactions of 
serially diluted template DNA for each gene, plotting the log concentration vs. Ct, and then 
calculating the efficiency as  (Yuan et al., 2008). The ΔΔCt method results in a fold 
amplification value that incorporates the test gene expression and the reference gene expression. 
If the gene-specific amplification efficiencies of the sample reaction and plate control reaction, 
Pc, (test group, T, and reference group, R) are close to equal, the various efficiencies will cancel 
out and the equation for fold amplification value can be simplified quite a bit. The formula for 
fold amplification value determination with the assumption of equal amplification efficiencies is 
part of the Excel software included in the SBI System Biosciences Small RNA Quantitation kit 
and is as follows: 
 
The resulting value is a ratio of test expression to reference expression and can be further 
analyzed in many ways. It should be noted that as a ratio of expression it is sometimes beneficial 
to transform the fold amplification value to the negative reciprocal value for visualization 
purposes and some statistical uses. For example, a miRNA that shows half the expression in the 
test group as it does in the reference group will have a fold amplification value of 0.5. This value 
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can be transformed to its negative reciprocal, -2.0, showing that the miRNA was down-regulated 
two-fold. 
Experimental design 
All Ct values obtained from qPCR screening were analyzed using the ΔΔCt method. For 
the initial analysis, the treatment group LNCaP-104S zero hour was designated as the reference 
group and compared to all other treatment groups to calculate fold amplification values. In the 
initial analysis all fold amplification values deregulated above three-fold (up or down) were 
considered to be significant. All ΔΔCt calculations were performed in Microsoft Excel. 
M2. Cluster analysis 
Principle 
Much insight into the gene networks that regulate cellular processes can be offered by 
clustering analysis methods that attempt to identify groups of genes with related functions based 
on expression data (Gitter et al., 2010). The dynamic and complex nature of miRNA regulation 
makes clustering approaches to data analysis very useful. Hierarchical clustering can identify 
large-scale expression patterns of groups of miRNAs that have the same regulatory functions, 
and offers a way to visualize such groupings. Hierarchical clustering involves calculating 
distances between groups of genes (based on expression values) and then determining clustering 
solutions by iterative processing of all possible groupings. Two of the main considerations of 
clustering analysis are the method of measuring distance or similarity between groups and the 
type of hierarchical clustering algorithm that is used. The clustering software Gene Cluster 3.0 
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offers several options for determining distance or similarity (correlation, absolute correlation, 
Spearman rank correlation, Kendall’s tau, Euclidean distance, and city-block distance ) and for 
hierarchical clustering method (centroid linkage, single linkage, complete linkage, and average 
linkage)(de Hoon et al., 2004).  
Experimental design 
Hierarchical clustering was performed on the expression data obtained from the initial 
ΔΔCt calculations using the LNCaP-104S zero hour control. Data was clustered using correlation 
measurement for similarity and complete linkage. Both the miRNAs and the treatment arrays 
were hierarchically clustered and reordered. The analysis was visualized as a heat map and 
hierarchical clustering dendrogram with the visualization program Java Treeview (Page, 1996). 
M2. Additional comparisons 
Principle 
After the initial calculations of fold amplification values using LNCaP-104S zero hour as 
the control group, the comparison groupings were altered to study specific aspects of progression 
to drug resistance. Since the objective of the study involved identifying outliers in the expression 
set, it was necessary to calculate the average changes in expression and average deviation from 
the mean value. The measure of central tendency most suitable for this type of expression data is 
the geometric mean due to the multiplicative nature of the expression values and the decimal 
form of all down-regulated expression values. The formula for geometric mean is as follows: 
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and once the geometric mean has been calculated the geometric standard deviation can be 
calculated as 
 
where Ai denotes an individual fold amplification value. Once the standard deviation has been 
determined for each comparison set it is possible to determine z-scores in order to identify the 
miRNAs that show expression changes in the significant regions of either tail of the expression 
distribution. The standard formula for z-score is  
 
The standard z-score method was used for determining the z-score for all expression values 
greater than or equal to 1.0. Z-scores for negatively regulated miRNAs were calculated by 
negative reciprocal transformation of the fold amplification value and then addition of 2 before 
subtracting the mean value and dividing by the standard deviation: 
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Adding two insures that the distance of the negative reciprocal-transformed fold amplification 
value from the mean fold-expression value is accurate, since baseline expression change in our 
data was defined as 1.0 (meaning, a value of 1.0 denotes no change in expression). Additionally, 
also due to defining 1.0 as the baseline expression change, all geometric mean values determined 
to be less than 1.0 were negative reciprocal transformed for use in subsequent calculations. In 
order to avoid the assumption that miRNA expression is normally distributed, z-scores were only 
used as a means of selecting an arbitrary threshold and not as a means of assigning numerical 
significance.  
Experimental design 
The comparisons used are outlined in Table 1. The comparisons using LNCaP-104S one 
week and three weeks CDX treatment timepoints and the respective LNCaP-104S CS-FBS 
media treatment timepoints as reference samples show the relative miRNA expression changes 
due only to CDX treatment throughout the treatment regimen. The third comparison, relating 
LNCaP-104S cells treated with CDX for three weeks to a reference sample of LNCaP-104S cells 
treated with CDX for one week, is another way of studying progressive changes in miRNA 
expression during a CDX treatment regimen. This comparison better represents miRNA 
expression changes in the scenario of CDX treatment of androgen sensitive prostate cancer in 
concert with androgen deprivation therapy, since androgen deprivation dependent expression 
changes are not being adjusted for. Finally, the comparison of LNCaP-104S cells treated with 
CDX for three weeks to LNCaP-104R1 zero hour cells is another way to isolate only CDX-
dependent changes in miRNA expression. However, differences between this comparison and 
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the CDX versus CS-FBS comparisons are expected due to widespread cellular differences 
between the androgen sensitive LNCaP-104S cells and established androgen resistant LNCaP-
104R1 cells.   
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Table 1) Cell lines, treatments, and timepoints for test and reference samples of Comparisons A through D 
 
Test Sample Reference Sample 
Cell Line Treatment Timepoint Cell Line Treatment Timepoint 
A LNCaP-104S CSFBS/5µM CDX One week LNCaP-104S CSFBS One week 
B LNCaP-104S CSFBS/5µM CDX Three weeks LNCaP-104S CSFBS Three week 
C LNCaP-104S CSFBS/5µM CDX Three weeks LNCaP-104S CSFBS/5µM CDX One week 
D LNCaP-104S CSFBS/5µM CDX Three weeks LNCaP-104R1 CSFBS Zero hour 
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MiRNAs shown to be up- and down-regulated in the comparisons of Table 1 were 
subjected to cross-comparison analysis using Venn diagrams and the Venny tool available online 
(http://bioinfogp.cnb.csic.es/tools/venny/index.html).  Calculations of standard deviation and z-
score were performed by the previously described method. Expression fold-changes greater than 
two standard deviations from the mean expression fold-change (z-score less than -2 or greater 
than 2) were considered significant at this point in the data analysis. 
M2. Target prediction 
Principle 
In recent years there has been an attempt to develop public databases of miRNA targets 
so that researchers may draw conclusions from the huge amount of data becoming available. 
Some bioinformatic studies have resulted in the development of algorithm-based methods to 
predict the gene targets of known mature miRNA sequences based on several factors. The 
miRDB database presents predicted miRNA-target matches and assigns each match a score from 
50 to 100, representing the probability that the given mRNA is actually targeted. The target 
predictions are calculated using an algorithm designed to take into account seed conservation, 
other seed types, base composition, secondary structure, and location on the 3’ UTR. The 
developers used a machine learning strategy called Support Vector Machines (SVM) to 
systematically search known miRNA target data to optimize the algorithm. The database is 
public and can be searched online (http://mirdb.org/miRDB) (Wang, 2008; Wang and El Naqa, 
2008). Another publically available database of miRNA target predictions, TargetScan Human 
30 
 
release 5.1, can be searched as well. TargetScan Human assigns a context score to predicted 
targets based on site-type contribution, 3’ pairing contribution, local AU contribution, and 
position contribution (http:// targetscan.org/) (Friedman et al., 2009; Grimson et al., 2007; Lewis 
et al., 2005). 
Experimental design 
MiRNAs identified as significantly deregulated were inputs in target scan analysis using 
the internet-based target predictions software program miRDB (http://mirdb.org/miRDB). Target 
prediction results returned for up-regulated and down-regulated miRNAs were ranked first by the 
number of hits from the respective array of candidate miRNAs, and secondly by the arithmetic 
average of miRDB scores. Due to the large number of predicted target genes, only targets that 
received hits from multiple miRNAs and that received at least one hit with an miRDB score of 
80 or greater (for down-regulated miRNAs) or 90 or greater (for up-regulated miRNAs) were 
included in the final lists of predicted targets. The target predication program TargetScan Human 
(http://targetscan.org) was used for validation of predictions.  
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RESULTS 
To verify the expression of androgen receptor and the responsiveness of the LNCaP-104S 
cell line to androgen stimulation, western blotting for androgen receptor was performed with 
treated samples. Total protein extracted from LNCaP-104S cells treated with DHT and cells 
treated with Casodex at timepoints of zero hour, 24 hours, 48 hours, and 72 hours was subjected 
to SDS-PAGE and western blot, shown in Figure 1. LNCaP-104S cells treated with Casodex and 
treated with DHT did not show significant changes in androgen receptor expression from the 
zero hour. Androgen receptor expression in the LNCaP-104S was verified by western blotting.  
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Figure 1) Western blot of androgen receptor (110 kDa) in Casodex-treated androgen sensitive LNCaP-104S 
cells and in DHT-treated androgen sensitive LNCaP-104S cells at zero hour, 24 hours, 48 hours, and 72 hours 
timepoints; GAPDH loading control 
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The Ct results of miRNome screening in five LNCaP-104S treatment groups (zero hour, 
one week CS-FBS, three weeks CS-FBS, one week CDX, three weeks CDX) and the androgen 
independent zero hour LNCaP-104R1 group were processed using the ΔΔCt method with 
LNCaP-104S zero hour as the control group for each, and then compiled into a color-coded table 
of miRNA expression values, presented as Table 2. The standard rule of thumb that three-fold 
changes in expression, positive or negative, are to be considered significant miRNA expression 
changes was used as the initial method of looking at patterns across the five columns of ΔΔCt 
data. Fold amplification values with green backgrounds are greater than 3.0 and those with red 
backgrounds are less than -3.0 (corresponding to a threshold of 0.33 for untransformed fold 
amplification values). A value of 0.00 indicates that no cDNA amplification was detected, either 
because of extremely low miRNA expression level or an error in amplification.
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Table 2a) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4- 104S 3 wk CDX, 5- 0 hr 104R; All 
values are comparisons with 0 hr 104S; Green denotes change > 3 fold; Red denotes change < -3 fold 
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Table 2b) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4- 104S 3 wk CDX, 5- 0 hr 104R; All 
values are comparisons with 0 hr 104S; Green denotes change > 3 fold; Red denotes change < -3 fold 
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Table 2c) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4- 104S 3 wk CDX, 5- 0 hr 104R; All 
values are comparisons with 0 hr 104S; Green denotes change > 3 fold; Red denotes change < -3 fold 
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Table 2d) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4- 104S 3 wk CDX, 5- 0 hr 104R; All 
values are comparisons with 0 hr 104S; Green denotes change > 3 fold; Red denotes change < -3 fold 
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Table 2e) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4- 104S 3 wk CDX, 5- 0 hr 104R; All 
values are comparisons with 0 hr 104S; Green denotes change > 3 fold; Red denotes change < -3 fold 
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Table 2f) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4- 104S 3 wk CDX, 5- 0 hr 104R; All 
values are comparisons with 0 hr 104S; Green denotes change > 3 fold; Red denotes change < -3 fold 
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Table 2g) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4- 104S 3 wk CDX, 5- 0 hr 104R; All 
values are comparisons with 0 hr 104S; Green denotes change > 3 fold; Red denotes change < -3 fold 
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Table 2h) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4- 104S 3 wk CDX, 5- 0 hr 104R; All 
values are comparisons with 0 hr 104S; Green denotes change > 3 fold; Red denotes change < -3 fold 
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Table 2i) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4- 104S 3 wk CDX, 5- 0 hr 104R; All 
values are comparisons with 0 hr 104S; Green denotes change > 3 fold; Red denotes change < -3 fold 
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Table 2j) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4- 104S 3 wk CDX, 5- 0 hr 104R; All 
values are comparisons with 0 hr 104S; Green denotes change > 3 fold; Red denotes change < -3 fold 
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Table 2k) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4- 104S 3 wk CDX, 5- 0 hr 104R; All 
values are comparisons with 0 hr 104S; Green denotes change > 3 fold; Red denotes change < -3 fold 
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Table 2l) MiRNome expression screening; 1- 104S 1 wk CSFBS, 2- 104S 3 wk CSFBS, 3- 104S 1 wk CDX, 4- 
104S 3 wk CDX, 5- 0 hr 104R; All values are comparisons with 0 hr 104S; Green denotes change > 3 fold; 
Red denotes change < -3 fold 
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Complete linkage hierarchical clustering analysis was carried out using miRNAs that had 
fold amplification data for at least three of the five groups in Table 2. The horizontal order of 
miRNAs and the vertical order of treatment groups were arranged into clusters, with more 
similar elements ordered closer together in the heat map, presented in Figure 2. Up-regulated 
expression appears as red and down-regulated expression appears as green. Hierarchical cluster 
dendrograms were constructed for the miRNAs and treatments to visualize how individual 
miRNAs and treatments were grouped.  It can be seen that distinct clusters of up- and down-
regulated miRNA genes emerged from the hierarchical clustering exercise. Of the miRNAs 
included the in analysis, 199 exhibited general patterns of up-regulation with treatment, and 599 
exhibited general patterns of down-regulation. A cluster of 99 miRNAs showed a consistent 
pattern of strong up-regulation and a cluster of 241 miRNAs showed a consistent pattern of 
strong down-regulation. 
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Figure 2) Heat map of clustered miRNA expression across all treatment groups using LNCaP zero hour 
expression as reference 
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The raw Ct data was then processed by the ΔΔCt method using different treatment groups 
as reference groups than had been previously been used in an attempt to better analyze miRNA 
changes that occur due to the effects of CDX-treatment. Fold amplification values were 
determined according to the comparisons listed in Table1. The miRNAs were ranked according 
to fold amplification values for each comparison. Tables 3 and 4 contain the top ranked up-
regulated and down-regulated results, respectively. The miRNAs that are included in these tables 
have fold-amplification values that are at least two standard deviations removed from the mean 
change in expression for the comparison (this corresponds to z-scores ≥ 2.0 or ≤ -2.0; refer to 
Materials and Methods for a description of the method for determining z-scores). MiRNAs that 
have fold amplification values greater than three standard deviations above the mean are denoted 
with green backgrounds in Table 3, and those with fold amplification values greater than three 
standard deviations below the mean are denoted with red backgrounds in Table 3. The letter 
denotation of each comparison can be referenced in Table 1. Assigning significance based on z-
score proved to be a more conservative approach than the three-fold method and decreased the 
total number of miRNAs considered significant; the category containing the greatest number of 
significant miRNAs was the down-regulated portion of comparison D with 56 miRNAs, and  the 
up-regulated portion of comparison D included only 8 miRNAs. The average fold-changes in 
expression for comparisons A, B, and C were slightly negative (µA=0.959, µC=0.778, µD=0.608), 
but none exceeded more than 1.7-fold down-regulation. Comparison A had an average fold-
change in expression of 1.43. 
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Table 3) Up-regulated miRNAs in comparisons A through D with expression fold changes greater than two standard deviations above the mean 
fold change; µ is the geometric mean of all amplified miRNAs in the comparison; σ is one geometric standard deviation 
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Table 4) Down-regulated miRNAs in comparisons A through D with negative expression fold changes greater than two standard deviations 
below the mean fold change; µ is the geometric mean of all amplified miRNAs in the comparison; σ is one geometric standard deviation 
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Significantly deregulated miRNAs were then analyzed in a manner illustrated by the 
Venn diagrams in Figure 3. All miRNAs that showed three-fold deregulation in any of the 
comparison groups of Table 1 were included in the Venn diagrams for either up- or down-
regulated miRNAs, and a small number of miRNAs were included in both diagrams. The 
numbers in the figure represent the number of miRNAs in a specific section of the Venn 
diagram. In all, 60 miRNAs were up-regulated in Comparison B (three weeks CDX vs. three 
weeks CS-FBS) and at least one other comparison group. 17 miRNAs were up-regulated in CDX 
treated cells compared to CS-FBS-only treated cells at both one week and three weeks 
timepoints, Comparisons A and B. Two miRNAs, miR-RC-751 and miR-RC-308,  also showed 
significant up-regulation between the one week and three weeks CDX timepoints, Comparison 
C. Several miRNAs included in the Venn diagram analysis had also been deemed significant due 
to z-scores greater than 2.0 or less than -2.0, and these miRNAs are identified in red in Figure 3 
and Figure 4. 
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Figure 3) Venn diagram cross-comparison analysis of up-regulated miRNAs for comparisons A through D; 
miRNAs in red have fold changes of two standard deviations or greater above the mean fold change in at 
least one comparison 
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The down-regulated miRNAs in Figure 4 consists of 29 miRNAs that exhibited three-fold 
or greater down-regulation in Comparison B and either or both Comparison C and/or 
Comparison D. Only one miRNA, miR-RC-593, was significantly down-regulated at both the 
one week and three weeks CDX timepoints, Comparisons A and B. MiR-RC-593 was also down-
regulated in Comparison D, CDX treatment compared to androgen insensitive cells. 
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Figure 4) Venn diagram cross-comparison analysis of down-regulated miRNAs for comparisons A through 
D; miRNAs in red have fold changes of two standard deviations or greater below the mean fold change in at 
least one comparison 
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The primary objective of this study was to identify a group of miRNAs which show 
significantly altered expression during CDX treatment to be used for developing clinical 
screening procedures as well as for further investigation of cancer progression mechanisms. 
These candidate miRNAs were identified based on the previously described comparison methods 
and are presented in Table 5 as an array of primary candidate miRNAs. Up-regulated primary 
candidate miRNAs were chosen from the top-ranked miRNAs that had expression values greater 
than two standard deviations above the mean expression change in CDX treated cells at three 
weeks, compared to CS-FBS treated cells or to zero hour LNCaP-104R1 cells, Comparisons B 
and D. Since none of the very highly ranked up-regulated miRNAs were up-regulated in multiple 
comparisons, none of the miRNAs appearing in Figure 3 were included in the array of primary 
candidates. Candidate miRNAs for the down-regulated group were chosen on the condition that 
they showed at least two standard deviations of down-regulation in any comparison and also at 
least three-fold down-regulation in CDX treated cells at three weeks. Again, the top ranked 
miRNAs were given preference. We chose 28 primary candidate miRNAs, with 14 exhibiting 
overall up-regulation and 14 exhibiting overall down-regulation. The number of candidate 
miRNAs included in the primary candidates array was intentionally kept relatively low to 
facilitate results in the next stage of data analysis, target prediction. The order of miRNAs 
presented in Table 5 cannot objectively be considered the order of significance. 
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Table 5) Primary candidate array of most significantly deregulated candidate miRNAs 
Primary Candidate MicroRNAs 
Up-regulated Down-regulated 
miR-RC-640 miR-RC-301 
miR-RC-639 miR-RC-649 
miR-RC-576 miR-RC-291 
miR-RC-175 miR-RC-442 
miR-RC-623 miR-RC-759 
miR-RC-375 miR-RC-599 
miR-RC-272 miR-RC-220 
miR-RC-632 miR-RC-878 
miR-RC-622 miR-RC-407 
miR-RC-141 miR-RC-603 
miR-RC-562 miR-RC-528 
miR-RC-517 miR-RC-329 
miR-RC-309 miR-RC-490 
miR-RC-197 miR-RC-247 
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To serve as a more complete collection of candidate miRNAs for future screening 
purposes, a second array of miRNAs was constructed, referred to as the secondary array of 
candidate miRNAs and presented in Table 6. This array encompassed all the miRNAs included 
in the primary array, plus other significantly deregulated candidates. Any miRNA that had z-
scores greater 3.0 or less than -3.0 and any miRNA that was at least three-fold deregulated in 
Comparison B and one other comparison (all miRNAs listed in Figure 3 and Figure 4) were 
included as elements in the secondary array of candidate miRNAs. The secondary array consists 
of 102 upregulated miRNAs and 85 down-regulated miRNAs. 
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Table 6) Secondary candidate array of significantly deregulated candidate miRNAs 
Secondary Candidate MicroRNAs 
Up-regulated Down-regulated 
miR-RC-707 miR-RC-376  miR-RC-104 miR-RC-881 miR-RC-822  miR-RC-750 miR-RC-258 
miR-RC-682 miR-RC-761  miR-RC-796 miR-RC-556 miR-RC-140  miR-RC-702 miR-RC-303 
miR-RC-825 miR-RC-364  miR-RC-244 miR-RC-588 miR-RC-735  miR-RC-698 miR-RC-554 
miR-RC-680 miR-RC-557  miR-RC-874 miR-RC-523 miR-RC-326  miR-RC-671 miR-RC-589 
miR-RC-719 miR-RC-414  miR-RC-751 miR-RC-57 miR-RC-558  miR-RC-199 miR-RC-326 
miR-RC-751  miR-RC-564  miR-RC-672 miR-RC-857 miR-RC-247  miR-RC-538 miR-RC-329 
miR-RC-308   miR-RC-693  miR-RC-39 miR-RC-630 miR-RC-593   miR-RC-771 miR-RC-22 
miR-RC-556  miR-RC-843  miR-RC-674 miR-RC-26 miR-RC-590  miR-RC-301 miR-RC-527 
miR-RC-857  miR-RC-535  miR-RC-487 miR-RC-22 miR-RC-747  miR-RC-649 miR-RC-575 
miR-RC-726  miR-RC-46  miR-RC-638 miR-RC-587 miR-RC-710   miR-RC-291 miR-RC-559 
miR-RC-794  miR-RC-816  miR-RC-598 miR-RC-716 miR-RC-301  miR-RC-442 miR-RC-653 
miR-RC-591  miR-RC-101 miR-RC-412 miR-RC-866 miR-RC-649  miR-RC-759 miR-RC-545 
miR-RC-9  miR-RC-283  miR-RC-640 miR-RC-656 miR-RC-291  miR-RC-599 miR-RC-344 
miR-RC-395  miR-RC-345  miR-RC-639 miR-RC-238 miR-RC-442  miR-RC-628 miR-RC-256 
miR-RC-330 miR-RC-620  miR-RC-576 miR-RC-28 miR-RC-759  miR-RC-220 miR-RC-75 
miR-RC-14  miR-RC-157  miR-RC-175 miR-RC-678 miR-RC-599  miR-RC-590 miR-RC-448 
miR-RC-605  miR-RC-13 miR-RC-623 miR-RC-392 miR-RC-628  miR-RC-700 miR-RC-78 
miR-RC-380  miR-RC-238  miR-RC-375 miR-RC-283 miR-RC-220  miR-RC-878 miR-RC-534 
miR-RC-678  miR-RC-312  miR-RC-272 miR-RC-517 miR-RC-700  miR-RC-529 miR-RC-450 
miR-RC-7 miR-RC-393  miR-RC-632 miR-RC-309 miR-RC-878  miR-RC-343 miR-RC-327 
miR-RC-307  miR-RC-28  miR-RC-622 miR-RC-197 miR-RC-407  miR-RC-300 miR-RC-178 
miR-RC-449  miR-RC-286  miR-RC-141 miR-RC-761 miR-RC-603  miR-RC-247 miR-RC-227 
miR-RC-402  miR-RC-392  miR-RC-562 miR-RC-843 miR-RC-528  miR-RC-528 miR-RC-328 
miR-RC-257  miR-RC-461   miR-RC-477 miR-RC-799 miR-RC-530  miR-RC-407 miR-RC-422 
miR-RC-884 miR-RC-797 miR-RC-66 
 
miR-RC-340  miR-RC-12 miR-RC-375 
miR-RC-346  miR-RC-717 miR-RC-660 
 
miR-RC-738  miR-RC-452 miR-RC-304 
    
miR-RC-868  miR-RC-537 miR-RC-465 
    
miR-RC-63  miR-RC-603 miR-RC-288 
    
miR-RC-329 
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The top miRDB (miRNA DataBase, http://mirdb.org) target prediction results for the 
miRNAs of the up-regulated and down-regulated lists of the primary array of candidates are 
presented in Table 7 and Table 8, respectively. The miRDB score is the cumulative target score 
for a single miRNA and a single mRNA transcript assigned by the internet-based prediction 
software miRDataBase, with 100 being the highest score possible. The TargetScan Human 
column is checked if the miRNA-target prediction is validated by internet-based prediction 
database TargetScan Human. Refer to Materials and Methods for a description of how targets 
were chosen for inclusion in Figure 7 and Figure 8. Several genes are predicted targets of more 
than three up-regulated primary candidate miRNAs, including SH3TC2, CLASP2, AAK1, 
GTF2H1, and NARG1. The genes ZEB1 and ZEB2 are targeted by miR-RC-517 with a miRDB 
score of 100, the highest score possible. Also of note, the genes ZEB1, ZEB2, SLC7A11, TET2, 
TMEM170B, UBE2B, ALS2CR2, CYP20A1, ERRFI1, SH3TC2, SLC35B4, TNRC6B, 
ZKSCAN1, and ZNF826 are targeted by at least one up-regulated miRNA with a score of 99.0 or 
greater.
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Table 7) Predicted target genes of up-regulated miRNAs; TS column shows validation of target match with the TargetScan Human database 
(miR-1914 is not included in the TargetScan Human database) 
61 
 
Down-regulated miRNAs of the primary candidate array have 11 very significant 
predicted targets, but only ZNF776 is targeted by more than two miRNAs and receives at least 
one score of 80.0 or above. The genes LATS2 and ZKSCAN1 are both predicted targets of miR-
RC-407 and have miRDB scores of 99.0. The genes ZKSCAN1 and SH3TC2 are strongly 
predicted targets of miRNAs belonging to both the up-regulated and down-regulated lists of the 
primary candidates array. 
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Table 8) Predicted target genes of down-regulated miRNAs; TS column shows validation of target match with 
the TargetScan Human database (miR-1972 is not included in the TargetScan Human database) 
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DISCUSSION 
In this study we sought to investigate the deregulation of miRNAs in human prostate 
cancer treated with the anti-androgen drug Casodex and to shed light on the possible functional 
roles of deregulated miRNAs in the progression of prostate cancer cells toward anti-androgen 
resistance. Extensive analysis of expression for almost all known human miRNA sequences was 
carried out, and an array of deregulated miRNAs was identified, as were several putative 
regulatory target genes. The data suggest that some form of miRNA regulation is at play in the 
progression of androgen sensitive LNCaP cells to a castration resistant phenotype. Quantitative 
PCR is the most sensitive method of measuring gene expression available, so large changes 
measured in the expression of miRNA genes can be taken as a reflection of cellular regulation 
involving cancer progression processes and the effects of CDX treatment. The comparisons of 
expression values that were carried out revealed that several miRNAs were up- and down-
regulated. Interestingly, the initial ΔΔCt method analysis and cluster analysis revealed that 
approximately 75% of the miRNAs screened shown some pattern down-regulation when prostate 
cancer cells were subjected to stimuli of androgen independence. This overall decrease in 
miRNA production might be a signal of general deregulation of cellular processes, contributing 
to more aggressive cancer phenotypes. 
The miRNAs miR-RC-301, miR-RC-442, miR-RC-291, and miR-RC-599 had the most 
widespread down-regulation of the miRNAs screened. They were significantly down-regulated 
in androgen sensitive cells treated with CDX for three weeks compared to androgen sensitive 
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cells treated only with CS-FBS, and they were also found to be down-regulated in androgen 
sensitive cells treated with CDX for three weeks compared to androgen insensitive LNCaP-
104R1 cells. MiR-RC-599 showed significant decrease in expression between the one week and 
three week timepoints of CDX treatment in androgen sensitive cells. These expression patterns 
strongly indicate that these miRNAs have high potential for being implicated in the regulation of 
progression to the androgen independent phenotype. There are known cancer roles for the 
miRNAs corresponding to our sequences miR-RC-301 and miR-RC-442. Hsa-miR-199a-5p has 
been shown to be down-regulated in the progression process of oral cancers in hamster models 
(Yu et al., 2009). This same down-regulated expression pattern was seen in our cancer 
progression model. Investigation into therapeutic targets for leukemia has revealed that miR-337 
down-regulation is associated with overexpression of the tyrosine kinase Lyn, possibly 
contributing to the rise of malignant phenotypes in certain types of leukemia (Hussein et al., 
2009). Again, this same expression pattern was seen in our model, suggesting that the activity of 
Lyn kinase could contribute to CDX-resistance. 
Another miRNA found to be consistently down-regulated was miR-RC-220. It was 
recently shown that repression of malignant characteristics and some cell cycle arrest at the G1/S 
transition are seen when knocked-down expression of this miRNA is restored in hepatocellular 
carcinoma cells. The same study presented evidence that the miRNA targets the mRNA of 
CCND2 (Cyclin D2) (Wang et al., 2010). We did not strongly predict CCND2 as a target of 
miRNA regulation most likely due to the array-based approach taken to target prediction, with 
preference given to targets that received multiple hits. The down-regulation of miR-RC-220 in 
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cells progressing to CDX-resistance may lead to decreased inhibition of cyclin D2 function and 
increased survival due to accelerated G1/S transition.  
We also found that miR-RC-590 was down-regulated during progression to CDX-
resistance. This result has been corroborated by a study of miRNA expression in clear renal cell 
carcinoma tissue samples, where it was found that miR-514 (corresponding to our miR-RC-590 
sequence) is very highly down-regulated compared to matched non-malignant samples. It is, 
however, unclear whether low miR-514 levels are part of a cancer affecter mechanism or just the 
result of an altered regulatory mechanism, as no correlation between miR-514 expression and 
tumor stage or survival were found (Jung et al., 2009). It was also determined in our study that 
the miRNA miR-RC-247 (corresponding to hsa-miR-184) is significantly down-regulated during 
CDX-treatment of androgen sensitive cells. There is evidence that miR-184 has tumor suppressor 
functions through indirect inhibition of the Akt pathway. It was found that miR-184 can bind to 
and repress the function of another miRNA, miR-205, which itself represses the enzyme SHIP2 
(thought to inhibit Akt signaling) (Yu et al., 2008). 
The miRNAs in the up-regulated list of primary candidates demonstrated less consistency 
in expression across our four comparison analyses, but still resulted in some important findings. 
Firstly, the two most highly up-regulated miRNAs in androgen sensitive cells treated with CDX 
for three weeks compared to androgen sensitive cells treated only with CSFBS were miR-RC-
640 and miR-RC-639, with 126.045 and 64.772 fold up-regulation respectively. Interestingly, 
these miRNA sequences arise from the same primary miRNA hairpin, being cleaved from 
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opposite arms of the hairpin by dicer. Increased expression of the primary hairpin transcript and 
subsequent retention of both possible strands suggests that these miRNAs are involved in CDX-
induced drug resistance. Another miRNA found to be significantly up-regulated in our study was 
miR-RC-197. This finding is contrary to the pattern found in one study that reported down-
regulation of miR-146a (corresponding to miR-RC-197) in androgen independent prostate 
cancer, leading to increased expression of its regulatory target ROCK1 (Lin et al., 2008). 
However, it may be the case that miR-146a down-regulation is an effect of depleted androgen 
levels and that the effects of anti-androgen binding include increased miR-146a expression. 
Two members of the miR-200 family exhibited significant differential expression and 
were included in the primary candidate array of up-regulated miRNAs, miR-RC-517 and miR-
RC-309. It has been shown by several studies that up-regulation of these miRNAs are important 
for migration of certain cancers. Mesenchymal (metastatic) ovarian cancer cells overexpress the 
miR-200 family miRNA miR-429 compared to non-metastatic ovarian cancer cells. Additionally, 
the transcription factors ZEB1 and ZEB2 are known targets of miR-429. ZEB1 and ZEB2 levels 
are decreased in ovarian cancer cells when miR-429 is overexpressed (Chen et al., 2011), 
corroborating the miRNA expression and target prediction results of our study. MiR-200a has 
also been implicated in migration through targeting of ZEB2 in nasopharyngeal carcinoma cells 
(Xia et al., 2010). 
The genes LATS2, ZKSCAN1, LPAR4, and VPS53 were the most highly predicted to be 
regulatory targets of down-regulated miRNAs, suggesting an increase in expression of the genes 
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in question. LATS2 is a known tumor suppressor gene that has lowered expression in a diverse 
array of cancers, including prostate cancer. In a genomic study of malignant mesothelioma cell 
lines, the majority of the studied lines showed deletion or mutation of the LATS2 gene. IT was 
also found that LATS2 inhibits the YAP oncogene by phosphorylation (Murakami et al., 2011). 
Another study showed that in breast and prostate tissues decreased expression of LATS2 is 
possibly due to a defective mutation in the transcription factor FOXP3 (Li et al., 2011). Given 
the very high score assigned to the miR-RC-407/LATS2 interaction by miRDB (99.0), it is 
extremely probable that the target prediction is accurate. However, more complex regulatory 
pathways than can be elucidated by this screening study alone may be at play. Two gene targets 
were predicted for both up- and down-regulated miRNAs of the primary candidate array.  
ZKSCAN1 is a strongly predicted target of miR-RC-623 and miR-RC-407. SH3TC2 is a 
strongly predicted target of multiple up- and down-regulated miRNAs. It is expected that in the 
case of multiple regulatory miRNAs specific for the same mRNA transcript, the effect of the up-
regulated miRNA would be phenotypically apparent, i.e. decreased expression of the target gene. 
It is important that the miRNA screening be replicated for the candidate miRNAs chosen 
from this preliminary investigation in matched samples of patient tumors before and following 
the acquisition of an androgen independent phenotype. Additionally, the genes predicted as 
targets in this study should be the focus of further investigations to verify both that expression of 
these genes are altered upon treatment with CDX and that these genes are indeed targeted by the 
deregulated miRNAs as predicted. 
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In conclusion, the genome-wide miRNA expression screening resulted in an array of both 
up-regulated and down-regulated candidate miRNAs that have altered expression in androgen 
sensitive LNCaP cells as a result of treatment with CDX, separate from the effects of androgen 
depletion alone. 28 miRNAs exhibiting differential expression in the process of acquiring drug 
resistance were compiled into an array of primary miRNA candidates for diagnostic and 
therapeutic use. These miRNAs could have clinical implications as part of a screening test to 
more accurately identify the level of progression to drug resistance or to predict the effectiveness 
of anti-androgen therapy in a patient. Uses of miRNA markers that would lead to more selective 
use of anti-androgen therapy would certainly be worthwhile if it would make it possible to avoid 
the certain decline in quality of life for patients undergoing cancer therapy. This study forms the 
groundwork for further studies to validate the expression profiles of the identified miRNAs and 
to characterize the putative miRNA-target interactions.  
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